Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis

EMBO Journal

Volumn 28, Issue 18, 2009, Pages 2719-2732

  Yan, Hong Li ^a   Xue, Geng ^a   Mei, Qian ^a   Wang, Yu Zhao ^a   Ding, Fei Xiang ^a   Liu, Mo Fang ^b   Lu, Ming Hua ^b   Tang, Ying ^a   Yu, Hong Yu ^c   Sun, Shu Han ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Hypoxia; MicroRNA 17 92 cluster; P53; Transcriptional repression

Indexed keywords

LUCIFERASE; MICRORNA; MICRORNA 17 92; MYC PROTEIN; PROTEIN P53; TATA BINDING PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING SITE; CELL HYPOXIA; CHROMATIN IMMUNOPRECIPITATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; GENE CLUSTER; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; TUMOR SUPPRESSOR GENE; WILD TYPE;

ANOXIA; APOPTOSIS; BINDING SITES; CACO-2 CELLS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; HUMANS; KINETICS; LUCIFERASES; MICRORNAS; MODELS, BIOLOGICAL; MULTIGENE FAMILY; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70349220767     PISSN: 02614189     EISSN: 14602075     Source Type: Journal    
DOI: 10.1038/emboj.2009.214     Document Type: Article

References (55)

1. Aguda BD, Kim Y, Piper-Hunter MG, Friedman A, Marsh CB (2008) MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc. Proc Natl Acad Sci USA 105: 19678-19683
2. Alarcon RM, Denko NC, Giaccia AJ (2001) Genetic determinants that influence hypoxia-induced apoptosis. Novartis Found Symp 240: 115-128
3. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297. Review
4. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104: 263-269
5. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu CG et al (2005) A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353: 1793-1801
6. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, Dell'Aquila ML, Alder H, Rassenti L, Kipps TJ, Bullrich F, Negrini M, Croce CM (2004) MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 101: 11755-11760
7. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL, Gleadle JM, Ragoussis J (2008) hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 14: 1340-1348
8. Castoldi M, Schmidt S, Benes V, Noerholm M, Kulozik AE, Hentze MW, Muckenthaler MU (2006) A sensitive array for microRNA expression profiling (miChip) based on locked nucleic acids (LNA). RNA 12: 913-920
9. Cheng AM, Byrom MW, Shelton J, Ford LP (2005) Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 33: 1290-1297
10. Chiou SK, Rao L, White E (1994) Bcl-2 blocks p53-dependent apoptosis. Mol Cell Biol 14: 2556-2563
11. Coller HA, Forman JJ, Legesse-Miller A (2007) 'Myc0ed messages': myc induces transcription of E2F1 while inhibiting its translation via a microRNA polycistron. PLoS Genet 3: e146
12. Croce CM, Calin GA (2005) miRNAs, cancer and stem cell division miRNAs, cancer, and stem cell division. Cell 122: 6-7. Review
13. Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B (1992) Definition of a consensus binding site for p53. Nat Genet 1: 45-49
14. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, Furth EE, Lee WM, Enders GH, Mendell JT, Thomas-Tikhonenko A (2006) Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 38: 1060-1065
15. Djelloul S, Forgue-Lafitte ME, Hermelin B, Mareel M, Bruyneel E, Baldi A, Giordano A, Chastre E, Gespach C (1997) Enterocyte differentiation is compatible with SV40 large T expression and loss of p53 function in human colonic Caco-2 cells. Status of the pRb1 and pRb2 tumor suppressor gene products. FEBS Lett 406: 234-242
16. Fink T, Lund P, Pilgaard L, Rasmussen JG, Duroux M, Zachar V (2008) Instability of standard PCR reference genes in adipose-derived stem cells during propagation, differentiation and hy-poxic exposure. BMC Mol Biol 9: 98
17. Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, Forloni M, Boldrini R, Donfrancesco A, Federici V, Giacomini P, Peschle C, Fruci D (2008) Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One 3: e2236
18. Geisberg JV, Struhl K (2004) Quantitative sequential chromatin immunoprecipitation, a method for analyzing co-occupancy of proteins at genomic regions in vivo. Nucleic Acids Res 32: e151
19. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88-91
20. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878
21. Hammond EM, Giaccia AJ (2005) The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun 331: 718-725. Review
22. Harris AL (2002) Hypoxia-a key regulatory factor in tumor growth. Nat Rev Cancer 2: 38-47
23. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y, Takahashi T (2005) A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 65: 9628-9632
24. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM (2005) A microRNA polycistron as a potential human oncogene. Nature 435: 828-833
25. Hebert C, Norris K, Scheper MA, Nikitakis N, Sauk JJ (2007) High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer 6: 5
26. Ho J, Benchimol S (2003) Transcriptional repression mediated by the p53 tumour suppressor. Cell Death Differ 10: 404-408. Review
27. Ho JS, Ma W, Mao DY, Benchimol S (2005) p53-dependent tran-scriptional repression of c-myc is required for G1 cell cycle arrest. Mol Cell Biol 25: 7423-7431
28. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M (2002) Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277: 3247-3257
29. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253: 49-53
30. Koumenis C, Alarcon R, Hammond E, Sutphin P, Hoffman W, Murphy M, Derr J, Taya Y, Lowe SW, Kastan M, Giaccia A (2001) Regulation of p53 by hypoxia: dissociation of transcrip-tional repression and apoptosis from p53-dependent transactiva-tion. Mol Cell Biol 21 : 1297-1310
31. Krieg AJ, Hammond EM, Giaccia AJ (2006) Functional analysis of p53 binding under differential stresses. Mol Cell Biol 26: 7030-7045
32. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, Calin GA, Ivan M (2007) A microRNA signature of hypoxia. Mol Cell Biol 27: 1859-1867
33. Lewis BP, Shih IH, Jones-Rhoades MW (2003) Prediction of mammalian micro RNA targets. Cell 115: 787-798
34. Liu T, Laurell C, Selivanova G, Lundeberg J, Nilsson P, Wiman KG (2007) Hypoxia induces p53-dependent transactivation and Fas/ CD95-dependent apoptosis. Cell Death Differ 14: 411-421
35. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408
36. Loyant V, Jaffré A, Breton J, Baldi I, Vital A, Chapon F, Dutoit S, Lecluse Y, Loiseau H, Lebailly P, Gauduchon P (2005) Screening of TP53 mutations by DHPLC and sequencing in brain tumours from patients with an occupational exposure to pesticides or organic solvents. Mutagenesis 20: 365-373
37. Marinescu VD, Kohane IS, Riva A (2005) MAPPER: a search engine for the computational identification of putative transcription factor binding sites in multiple genomes. BMC Bioinformatics 6: 79. ( http://mapper.chip.org/mapper/ mapper
38. Matsubara H, Takeuchi T, Nishikawa E, Yanagisawa K, Hayashita Y, Ebi H, Yamada H, Suzuki M, Nagino M, Nimura Y, Osada H, Takahashi T (2007) Apoptosis induction by antisense oligonu-cleotides against miR-17-5p and miR-20a in lung cancers over-expressing miR-17-92. Oncogene 26: 6099-6105
39. Murphy M, Hinman A, Levine AJ (1996) Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev 10: 2971-2980
40. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT (2005) c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435: 839-843
41. Saikumar P, Dong Z, Patel Y, Hall K, Hopfer U, Weinberg JM, Venkatachalam MA (1998) Role of hypoxia-induced Bax translo-cation and cytochrome c release in reoxygenation injury. Oncogene 17: 3401-3415
42. Sharpless NE, DePinho RA (2002) p53: good cop/bad cop. Cell 11 0 : 9-12
43. Singh B, Reddy PG, Goberdhan A, Walsh C, Dao S, Ngai I, Chou TC, O-Charoenrat P, Levine AJ, Rao PH, Stoffel A (2002) p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev 16: 984-993
44. Slee EA, O'Connor DJ, Lu X (2004) To die or not to die: how does p53 decide? Oncogene 23: 2809-2818. Review
45. Stempien-Otero A, Karsan A, Cornejo CJ, Xiang H, Eunson T, Morrison RS, Kay M, Winn R, Harlan J (1999) Mechanisms of hypoxia-induced endothelial cell death. Role of p53 in apoptosis. J Biol Chem 274: 8039-8045
46. Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ (1999) Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 274: 10911-10915
47. Takakura S, Mitsutake N, Nakashima M, Namba H, Saenko VA, Rogounovitch TI, Nakazawa Y, Hayashi T, Ohtsuru A, Yamashita S (2008) Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci 99: 1147-1154
48. Tanzer A, Stadler PF (2004) Molecular evolution of a microRNA cluster. J Mol Biol 339: 327-335
49. Uetake Y, Sluder G (2007) Cell-cycle progression without an intact microtuble cytoskeleton. Curr Biol 17: 2081-2086
50. Volinia S, Calin GA, Liu CG (2006) A micro RNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261
51. Wang L, Wu Q, Qiu P, Mirza A, McGuirk M, Kirschmeier P, Greene JR, Wang Y, Pickett CB, Liu S (2001) Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches. J Biol Chem 276: 43604-43610
52. Weinmann M, Jendrossek V, Güner D, Goecke B, Belka C (2004) Cyclic exposure to hypoxia and reoxygenation selects for tumor cells with defects in mitochondrial apoptotic pathways. FASEB J 18: 1906-1908
53. Woods K, Thomson JM, Hammond SM (2007) Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem 282: 2130-2134
54. Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, Henderson JM, Kutok JL, Rajewsky K (2008) Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9: 405-414
55. Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L (2003) PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA 100: 1931-1936